Search results

Ongoing media statements relating to nuclear medicine production.

Research on the mechanism of cell death has insights to bring progress on neurodegenerative diseases and plant biosecurity.

ANSTO plays a leading role in measuring and characterising fine particles from a range of locations around Australia and internationally.

ANSTO and the User Meeting 2024 organising committee celebrate this years award recipients. 

Two approaches use existing low cost and low energy technologies to reuse stockpiled waste from mining operations - capturing carbon dioxide in the form of valuable carbonate minerals.

The nuclear medicine community has welcomed the Australian Government’s decision to provide $30 million in funding to ANSTO for the design of a new nuclear medicine manufacturing facility.

Professor of Soil Science at The University of Queensland, Peter Kopittke and partner investigator Prof Enzo Lombi of the University of SA are very optimistic about the use of a new synchrotron-based imaging technique that captures in 3D the complex interaction of soil and root.

Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer is now available in Australia

ANSTO provides a range of capabilities using neutrons, X-rays and infrared radiation to study the solids, liquids and gases that might be found in materials in our solar system and beyond.

The new Micro Computed Tomography (MCT) beamline is the first instrument to become operational as part of the $94 million Project BRIGHT program, which will see the completion of eight new beamlines at ANSTO’s Australian Synchrotron.

Atomic structure of new cathode material for sodium ion batteries helps explain long life

Creating a global energy system that is both environmentally and economically sustainable is unquestionably one of the largest challenges facing the scientific and engineering communities.

The Detection & Imaging group builds on ANSTO’s 70-year history of scientific achievements and contributions in meeting the nuclear needs of industry, globally.

ANSTO to receive a new grant to continue to fight chronic kidney disease killer in Sri Lanka.

Clarity Pharmaceuticals is building on comprehensive work on chelators carried out at ANSTO.

An international team led by ANSTO has been awarded a prestigious program grant from the Foundation for Australia-Japan Studies.